At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
3,4-Methylenedioxymethamphetamine +1 moredrug
Likely dose
3,4-Methylenedioxymethamphetamine 0.75mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Stimulant Drugs on Social Perception
In Brief
A Phase 1 clinical trial evaluating 3,4-Methylenedioxymethamphetamine and methamphetamine for Healthy and MDMA ('Ecstasy'). Completed, enrolled 36 participants across 1 site.
Detailed Summary
The study will improve our understanding of the "prosocial" effects of ± 3,4-Methylenedioxymethamphetamine (MDMA), relative to a prototypical stimulant, methamphetamine (MA). The investigators seek to characterize the "uniquely social" effects of MDMA.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy, MDMA ('Ecstasy')
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJun 2016
Primary CompletionAug 2018
First PostedDec 2018
TodayJul 2026
First PostedDec 31, 2018
Enrollment StartJun 1, 2016
Primary CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.5 years ago
Interventions
3,4-Methylenedioxymethamphetaminedrug
Participants will be given 0.75mg/kg of 1.5mg/kg MDMA
methamphetaminedrug
Please see above.